These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32571890)

  • 1. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
    Ngoi NY; Sundararajan V; Tan DS
    Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.
    Gupta N; Huang TT; Horibata S; Lee JM
    Pharmacol Res; 2022 Apr; 178():106162. PubMed ID: 35259479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the replication stress response through synthetic lethal strategies in cancer medicine.
    Ngoi NYL; Pham MM; Tan DSP; Yap TA
    Trends Cancer; 2021 Oct; 7(10):930-957. PubMed ID: 34215565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
    Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
    Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
    Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
    Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL; Willmore E; Prendergast L; Curtin NJ
    Br J Cancer; 2024 Sep; 131(5):905-917. PubMed ID: 38965423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer.
    Tang Q; Wang X; Wang H; Zhong L; Zou D
    Cancer Biol Med; 2024 Feb; 20(12):915-21. PubMed ID: 38318945
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
    Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
    Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
    Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
    Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
    Yang SH; Kuo TC; Wu H; Guo JC; Hsu C; Hsu CH; Tien YW; Yeh KH; Cheng AL; Kuo SH
    World J Gastroenterol; 2016 Aug; 22(32):7275-88. PubMed ID: 27621574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the replication stress response in cancer.
    Forment JV; O'Connor MJ
    Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress.
    Liu S; Opiyo SO; Manthey K; Glanzer JG; Ashley AK; Amerin C; Troksa K; Shrivastav M; Nickoloff JA; Oakley GG
    Nucleic Acids Res; 2012 Nov; 40(21):10780-94. PubMed ID: 22977173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.